Infinium Global Research Orphan Drugs Market | Page 2

Orphan Drugs Market: Trends and Forecasts up to 2024
The Infinium Global Research analyzes the report of Orphan Drugs Market over the
period of 2018 to 2024. This report also provides detailed qualitative and
quantitative analyses of the market dynamics, market size and future trends in
Global Orphan Drugs Market. It will help a lot of decision makers to develop
strategies and find new opportunities in the Global markets of Orphan Drugs.
The report covers market changing aspects including drivers, restraints,
opportunities, and trends expected to encouragement the expansion of the Orphan
Drugs Market during the said period. The report also provides market
attractiveness analysis, by geography, and market share analysis, by key players
respectively. Some of the prominent participants in the Global Orphan Drugs
Market are Alexion Pharmaceuticals, Eisai Co. Ltd., Bayer AG, Biogen Inc, Eli Lilly
and Company, AstraZeneca plc., GlaxoSmithKline and Johnson & Johnson.
According to report the global orphan drugs market is projected to grow at a CAGR
of 6.5% over the forecast period of 2018-2024.
For More Details Get Free Few Sample Pages of this Premium Report: -
https://www.infiniumglobalresearch.com/reports/sample-request/1619
Orphan drugs are medicinal products intended for diagnosis, prevention or
treatment of life-threatening or very serious diseases or disorders that are rare. A
disease or disorder is defined as rare in Europe when it affects less than 1 in 2,000
citizens. These drugs are called as orphan as pharmaceutical companies have small
interest in developing and marketing these drugs as these are intended for only a
small number of patients. For drug companies, the extremely high cost of bringing a
medicinal product to market would not be recovered by the anticipated sales of
such medicines. As a result the potential market for new drug treatment is also
small and the drug companies industry would actually incur a financial loss.
These drugs are used to treat the population suffering from the very serious, but
rare diseases for which no treatment available. There are around 25 to 30 million
people are affected by this diseases in Europe. The awareness about the orphan
drug is growing rapidly across the world that further leads to the growing adoption
of orphan drug act in the japan, Australia, Europe and others countries to stimulate
research and development in the orphan drug.
The orphan drug market segmented as diseases indication, product type, and
distribution channels. The segment dieses type is further divided into sub segment
including Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology,
2
© Infinium Global Research